Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Edwards Lifesciences on Tuesday, setting a price target of $106, which is approximately 11.30% above the...
Shares of Edwards Lifesciences hit an all-time high today after reporting Q1 earnings and revenue yesterday that beat analyst estimates. Shres are up 5% in afternoon trading.
Raymond James analyst Jayson Bedford maintained a Buy rating on Edwards Lifesciences on Wednesday, setting a price target of $101, which is approximately 12.69% above the present...
(Thursday Market Open) It’s a busy day for the airlines as three major carriers report and investors wait to hear what they might say about summer travel trends. In the...
Edwards Lifesciences EW shares soared 6.3% in the last trading session to close at $95.24. The move was backed by solid volume with far more shares changing hands than in a normal...
You can’t keep this optimistic market down for much longer than two days, so it’s no surprise to see stocks bounce back on Wednesday for their first positive session...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Neutral | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Buy |
| Summary | Strong Buy | Buy | Sell | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 320.02 | 320.24 | 313.28 | +5.00 | +1.59% | 19.00M | NASDAQ | |||
| 2,337.35 | 2,337.35 | 2,293.04 | +22.58 | +0.98% | 1.26M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 226.42 | 228.44 | 222.88 | -0.36 | -0.16% | 12.24M | NYSE | |||
| 46.65 | 49.81 | 45.72 | -4.53 | -8.85% | 79.21M | NYSE | |||
| 7.59 | 7.71 | 7.34 | +0.29 | +3.97% | 16.21M | NYSE | |||
| 1.15 | 1.22 | 1.11 | -0.0500 | -4.17% | 21.92M | NYSE | |||
| 0.8223 | 0.00 | 0.00 | +0.0228 | +2.85% | 3.71M | NYSE | |||
| 117.00 | 117.64 | 114.46 | +1.62 | +1.40% | 8.57M | NYSE | |||
| 15.93 | 16.29 | 15.02 | +0.99 | +6.63% | 8.64M | NYSE | |||
| 36.08 | 36.18 | 35.89 | +0.57 | +1.61% | 67.35K | OTC Markets | |||
| 67.53 | 68.50 | 65.01 | +4.46 | +7.07% | 12.59M | NYSE | |||
| 3.39 | 3.57 | 3.12 | +0.230 | +7.28% | 424.48K | NASDAQ | |||
| 20.09 | 21.02 | 19.41 | -1.06 | -5.01% | 92.10M | NYSE | |||
| 161.01 | 164.72 | 155.60 | +1.53 | +0.96% | 2.94M | NYSE |
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.